The Annual Physical Is Outdated
Your company's executive health program—or your insurance plan—covers an annual physical. You get a blood draw. Two weeks later, your doctor calls and says, "Everything looks fine."
How does he know?
Because he looked at 12 biomarkers. Maybe 15 if he's thorough. Total cholesterol, LDL, HDL, triglycerides, glucose, kidney function, liver function, a few others.
Twelve markers. That's your entire metabolic snapshot according to conventional medicine.
Here's what he didn't order, didn't look at, and probably doesn't think about: the 45+ biomarkers that actually tell you whether your metabolic house is on fire or not.
The annual physical was designed in 1995 for disease detection, not performance optimization. It screens for heart attacks and diabetes after they're already forming. It doesn't show you the early metabolic dysfunction that precedes disease by 5-10 years.
And if you're an executive in your 40s, 50s, or early 60s, early detection is the entire game. The difference between catching insulin resistance at HOMA-IR 2.5 versus 4.0 is the difference between 8 weeks of intervention versus 18 months of escalating treatment complexity.
Your annual physical can't see that. It sees one glucose number at one moment in time. That's it.
This is why executives are switching to comprehensive blood panels. Function Health, Superpower, WellnessFX, and similar platforms have disrupted executive health by doing something straightforward: ordering the biomarkers that actually matter.
But here's the challenge: if you're considering comprehensive testing for the first time, which 7 biomarkers matter most?
Let's walk through them.
The Problem With "Fine"
Before we get to the 7 markers, let's talk about what your doctor means when he says your results are "fine."
He means: "Nothing is critically abnormal. Nothing requires immediate intervention."
What he does not mean: "Your metabolic health is optimal. You're positioned for longevity and performance."
These are completely different statements.
An executive can have all "normal" annual physical markers—textbook LDL, textbook glucose, textbook kidney function—while simultaneously being insulin resistant, systemically inflamed, cardiovascular-at-risk, and hormonally declining.
The annual physical doesn't catch this because it doesn't look for it.
Example: James is 48. His annual physical shows:
- Total cholesterol: 210 (normal, <200 is ideal, but <240 is normal)
- LDL: 130 (normal, <100 is ideal, <160 is normal)
- HDL: 45 (normal, >40 for men)
- Triglycerides: 140 (normal, <150 is normal)
- Fasting glucose: 98 (normal, <100 is fasting normal)
His doctor reviews and says, "You're fine. Keep doing what you're doing."
James feels reassured. He's "fine." He has no acute risk factors. He doesn't have high cholesterol. He doesn't have diabetes.
But when James runs a comprehensive panel, here's what appears:
- ApoB: 145 (atherogenic; >130 confers elevated cardiovascular risk)
- HOMA-IR: 3.4 (insulin resistant; optimal is <1.5)
- hs-CRP: 5.2 (elevated inflammation; <1.0 is optimal)
- LDL particle count: 1,950 (small, dense LDL particles; these are the cardiovascular-damaging particles)
- Free testosterone: 14 (declining; normal for his age is 15-24)
- HbA1c: 5.8% (pre-diabetic range; normal is <5.7%)
- Homocysteine: 14 (elevated; optimal is <10)
James isn't "fine." He's 5-8 years ahead of a metabolic crisis if nothing changes.
His annual physical didn't see any of this. Because his annual physical wasn't looking.
Marker #1: HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)
What it is: A calculated score that reveals whether your cells are responsive to insulin or resistant to it.
Why your doctor didn't check it: It's not part of standard preventive screening. It requires calculating from fasting glucose and fasting insulin, and most primary care practices don't order fasting insulin because they don't think about insulin resistance as a primary health driver.
Why it matters: Insulin resistance is the root cause of 80%+ of metabolic dysfunction in executive populations. It precedes Type 2 diabetes by 5-10 years. It drives weight gain, systemic inflammation, cardiovascular disease, hormonal decline, and accelerated aging.
If you have HOMA-IR over 2.5, you're insulin resistant. Your cells aren't listening to your insulin signal. That means your pancreas is working harder to clear glucose. Your fasting insulin is elevated. Your metabolic rate is suppressed. Your body is storing fat preferentially and resisting weight loss.
The ranges:
- <1.5: Optimal
- 1.5–2.5: Borderline
- 2.5–4.0: Insulin resistant
4.0: Severe insulin resistance
What happens at each level:
At HOMA-IR 2.0, lifestyle modifications (diet, exercise, sleep) can normalize your metabolism.
At HOMA-IR 3.0+, lifestyle alone has a low ceiling. You need pharmaceutical intervention (GLP-1 agonists are the gold standard) to shift your metabolic phenotype.
At HOMA-IR 4.0+, you're in metabolic syndrome territory. Your risk profile for Type 2 diabetes, cardiovascular disease, and kidney dysfunction is dramatically elevated.
Clinical action: If you're an executive with HOMA-IR >2.5, you're insulinemic (your insulin levels are elevated), and this is driving metabolic dysfunction. Identifying this now—before your glucose rises enough to trigger a diabetes diagnosis—is the entire point of comprehensive testing.
Your annual physical has no mechanism to catch this.
Marker #2: hs-CRP (High-Sensitivity C-Reactive Protein)
What it is: A marker of systemic inflammation. It measures how much inflammatory cytokine activity your body is running at baseline.
Why your doctor didn't check it: It's often considered a "research marker" rather than a clinical one. Some GPs order it, but it's not standard. And even when they do, they only worry about it if it's >10, which is the acute inflammation range. Chronic elevation at 3-5 doesn't trigger action in conventional medicine.
Why it matters: Inflammation is the biological driver of aging. Elevated hs-CRP at 3.0+ is associated with:
- Accelerated vascular aging and atherosclerosis progression
- Elevated cardiovascular event risk (heart attack, stroke)
- Increased dementia risk
- Joint and connective tissue degeneration
- Thyroid autoimmunity
- Metabolic dysfunction
An executive with hs-CRP of 5.0 has inflammation running at a level that compounds every other health risk factor he has. If his LDL particle count is elevated, the inflammation accelerates atherosclerosis. If his testosterone is declining, the inflammation accelerates muscle loss. If he's insulin resistant, the inflammation worsens his metabolic phenotype.
Inflammation isn't a symptom in this context. It's a driver.
The ranges:
- <1.0: Optimal
- 1.0–3.0: Normal (acceptable, but not optimal)
- 3.0–10.0: Elevated chronic inflammation
10.0: Acute inflammation (usually following infection or injury)
Clinical action: If you're an executive with hs-CRP 3.0+, you need to understand the root driver of your inflammation. Is it from metabolic dysfunction (insulin resistance drives inflammation)? Gut dysbiosis? Chronic stress? Sleep deprivation? Omega-3 deficiency? Excessive seed oil consumption?
A competent clinician will dig into the root cause and design an intervention protocol. Your annual physical sees the hs-CRP result and says nothing, because hs-CRP isn't on your annual physical.
Marker #3: ApoB (Apolipoprotein B)
What it is: The structural protein that carries atherogenic (cardiovascular-damaging) lipid particles in your bloodstream. ApoB is a direct measure of your particle burden—how many lipid particles you have, regardless of cholesterol content.
Why your doctor didn't check it: Conventional medicine is still anchored in total cholesterol and LDL cholesterol. These metrics are familiar. ApoB is "new" (it's actually been around for decades, but it's gained clinical traction only recently). Insurance covers ApoB testing, but most primary care practices order what they know, and they know LDL.
Why it matters: This is arguably the most important lipid metric for cardiovascular risk, and 95% of executives have never had it measured.
Here's the critical nuance: LDL cholesterol and ApoB can be dramatically misaligned.
You can have:
- LDL cholesterol 100 and ApoB 140 (your LDL looks good, but you're carrying a lot of atherogenic particles)
- LDL cholesterol 150 and ApoB 90 (your LDL looks elevated, but your particle burden is low)
The second scenario is much lower risk than the first.
Why? Because atherosclerosis progresses based on the number of lipid particles infiltrating your arterial walls, not the amount of cholesterol inside them. One LDL particle carries one ApoB molecule. If your ApoB is high, you have a lot of particles. Even if each particle is "LDL-like," the number is what matters for vascular risk.
Conventional medicine has built a whole cardiovascular prevention strategy on LDL cholesterol, which is why executives with "normal" LDL still have heart attacks. The real risk factor—particle number—isn't being measured.
The ranges:
- <90: Optimal
- 90–130: Normal, but range-dependent
130: Elevated cardiovascular risk
160: High cardiovascular risk
Clinical action: If you're an executive with ApoB >130, you have atherogenic dyslipidemia. This requires intervention: statins (if indicated), diet modifications, possibly PCSK9 inhibitors in advanced cases, and monitoring. Your annual physical will never measure this, so your actual cardiovascular risk will remain invisible.
Marker #4: Free Testosterone (Not Just Total Testosterone)
What it is: The bioavailable testosterone—the fraction of your testosterone that's actually available for your cells to use. It's distinct from total testosterone, which includes testosterone bound to sex hormone-binding globulin (SHBG) and unavailable.
Why your doctor didn't check it: Most primary care practices order total testosterone and call it a day. Free testosterone requires a second assay (or calculation from total testosterone and SHBG). It's more expensive. And primary care doctors often don't think about testosterone optimization in men unless the patient complains of erectile dysfunction.
Why it matters: Testosterone is the metabolic hormone for men. It:
- Drives muscle protein synthesis
- Suppresses fat storage and promotes fat oxidation
- Maintains cardiovascular function
- Preserves bone density
- Supports cognitive function and mood
- Maintains sexual function
Testosterone declines ~1% per year in healthy aging men. But in metabolically damaged men—those with high insulin resistance, elevated inflammation, or chronic stress—testosterone can decline 2-3% per year.
By age 55, an executive who started at a healthy 650 total testosterone might now be at 450. His total testosterone "looks normal" (cutoff is usually 300-350), so his doctor doesn't worry.
But his free testosterone is 12 pg/mL, when optimal for his age is 16-24.
This explains why he's losing muscle mass, gaining abdominal fat, experiencing cognitive fog, and noticing declining sexual function—all while his "testosterone is fine."
The ranges:
- <12 pg/mL: Low (hypogonadism)
- 12–16: Borderline low
- 16–24: Optimal (age-dependent)
24: High (age-dependent)
Clinical action: If you're an executive 45+ with free testosterone <16 pg/mL, you're experiencing hypogonadism (even if total testosterone "looks fine"), and you need treatment. The evidence base is solid: testosterone replacement therapy in hypogonadal men improves body composition, cardiovascular function, cognitive performance, and quality of life.
Your annual physical won't measure free testosterone, so this opportunity will be missed.
Marker #5: Complete Thyroid Panel (Not Just TSH)
What it is: A complete assessment of thyroid function, including TSH (thyroid-stimulating hormone), free T4, free T3, and thyroid antibodies.
Why your doctor checked only TSH: It's the reflex screening test. TSH rises when thyroid function falls, so TSH is considered the "screening" marker. If TSH is normal, the thinking goes, the thyroid is fine.
This is a massive blind spot.
Why it matters: Thyroid dysfunction exists on a spectrum, and TSH is a late marker. You can have:
- Optimal free T3 and free T4 with an elevated TSH (early thyroid decline)
- Low free T3 with normal free T4 and TSH (Type 2 hypothyroidism; T4-to-T3 conversion is impaired)
- Hashimoto's thyroiditis (elevated TPO and thyroglobulin antibodies) with normal TSH (autoimmune thyroid disease in the early stage)
- Low free T3 with elevated reverse T3 (T4-to-reverse T3 conversion is elevated, suppressing metabolic rate)
All of these can coexist with a "normal" TSH.
The symptoms are real: fatigue, brain fog, weight gain, cold intolerance, depression, and slowed metabolism. But the TSH "says you're fine," so conventional medicine misses it.
For executives, the most common pattern is: normal TSH, low-normal free T3, elevated reverse T3. This pattern suggests chronic stress, overtraining, caloric deficit, or metabolic adaptation. The result is a suppressed metabolic rate and difficulty losing weight despite diet and exercise adherence.
The ranges:
- TSH: 0.5–2.5 mIU/L (optimal for most, especially if symptomatic)
- Free T4: 10–20 pmol/L (optimal in upper half of range)
- Free T3: 4.0–8.0 pmol/L (optimal in upper half of range)
- Reverse T3: <250 pmol/L (lower is better; high reverse T3 suppresses metabolism)
- TPO antibodies: <35 IU/mL (higher suggests autoimmunity)
- Thyroglobulin antibodies: <40 IU/mL (higher suggests autoimmunity)
Clinical action: If you're an executive with a "normal" TSH but symptoms of hypothyroidism—fatigue, brain fog, weight gain despite good diet—run a complete thyroid panel. You may have one of the patterns above. If identified, these are highly treatable with thyroid hormone optimization or T4/T3 replacement protocols.
Your annual physical checked TSH and called it thyroid assessment. It wasn't.
Marker #6: HbA1c (Hemoglobin A1c, Glycated Hemoglobin)
What it is: A measure of your average blood glucose over the past 2-3 months. It reflects how much glucose is binding to your red blood cells—a sign of elevated circulating glucose.
Why your doctor might have checked it (but probably misinterpreted it): HbA1c is standard screening for diabetes. But the cutoff for "prediabetes" is 5.7%, and the cutoff for "diabetes" is 6.5%.
Why it matters: The conventional interpretation is binary: below 5.7% is "normal," 5.7–6.4% is "prediabetes," and 6.5%+ is "diabetes."
But metabolic health isn't binary. HbA1c 5.9% isn't "fine." It's in the prediabetic range, and it indicates sustained glucose elevation that's damaging your microvasculature, accelerating aging, and signaling insulin resistance.
An executive with HbA1c 5.9% has been running elevated glucose for months. His glycation (glucose binding to proteins) is in progress. His endothelial function is declining. His cardiovascular risk is rising.
Conventional medicine says, "You don't have diabetes. Come back in a year."
Metabolic medicine says, "You're in the prediabetic range. We need intervention now to prevent disease progression."
The ranges:
- <5.7%: Normal
- 5.7–6.4%: Prediabetic (intervention recommended)
- 6.5%+: Diabetic
Clinical action: If you're an executive with HbA1c 5.7%+, you need to intervene. This doesn't mean you have diabetes. It means your glucose control is declining, and the window to reverse this is now—before it becomes a medical diagnosis.
The intervention isn't waiting. It's GLP-1 therapy, dietary modification, exercise, and close monitoring. Catching this at HbA1c 5.9% versus 6.8% is the difference between an 8-week intervention and a 12-month protocol.
Your annual physical probably checked HbA1c (many do now), but if it came back at 5.9%, your doctor likely said, "You're fine." He meant: "You don't have diabetes yet."
Marker #7: Homocysteine
What it is: An amino acid that's a byproduct of methionine metabolism. Elevated homocysteine reflects problems with methylation (the cellular process that regulates gene expression, detoxification, and DNA synthesis).
Why your doctor didn't check it: It's not standard preventive screening. Some functional medicine practitioners check it, but conventional medicine mostly ignores it unless it's dramatically elevated (>15) in the context of vascular disease.
Why it matters: Elevated homocysteine (>10 μmol/L) is associated with:
- Vascular endothelial dysfunction
- Elevated thrombotic risk (blood clot risk)
- Accelerated atherosclerosis
- Alzheimer's disease and dementia risk
- Epigenetic dysfunction (poor gene expression regulation)
Homocysteine is one of the clearest biomarkers of aging and metabolic stress.
If your homocysteine is elevated, it suggests:
- B12 or folate deficiency
- MTHFR polymorphism (genetic variation affecting methylation)
- High methionine intake relative to folate/B12
- Elevated oxidative stress
- Kidney dysfunction
The ranges:
- <10 μmol/L: Optimal
- 10–15: Elevated, intervention recommended
15: Significantly elevated, treatment indicated
Clinical action: If you're an executive with homocysteine >10, supplementation with methylfolate, methylB12, and betaine can normalize levels within 8-12 weeks. This is a highly addressable risk factor that's completely invisible to your annual physical.
How These 7 Markers Work Together
Here's why these specific 7 matter more than the 12 on your annual physical:
HOMA-IR + ApoB + hs-CRP = Metabolic and cardiovascular syndrome
If you have HOMA-IR >2.5 AND ApoB >130 AND hs-CRP >3, you're in a high-risk constellation. You have insulin resistance (metabolic), atherogenic dyslipidemia (cardiovascular), and systemic inflammation (aging accelerant). These three together compound each other's damage.
Free testosterone + TSH + HbA1c = Hormonal and metabolic aging
If your free testosterone is declining, your thyroid function is suboptimal, and your HbA1c is rising, you're experiencing metabolic and endocrine aging. Conventional medicine sees these as separate issues. They're actually one problem: declining metabolic capacity.
Homocysteine + hs-CRP = Epigenetic and vascular risk
Elevated homocysteine and hs-CRP together indicate epigenetic stress, poor methylation, and vascular dysfunction. This is the constellation that precedes Alzheimer's and cardiovascular disease.
An executive with all seven markers in suboptimal ranges isn't "fine." He's 5-10 years ahead of serious disease progression if nothing changes.
An executive with three of these markers elevated is in the metabolic decline phase. An executive with two is in the early optimization window.
Your annual physical cannot assess any of this*. By definition, it can't.
The Cost of Knowing vs. The Cost of Not Knowing
Let's talk economics.
A comprehensive blood panel costs $500–$800. Let's say $700.
Your annual physical costs you nothing (covered by insurance) or maybe $200 (if you're in a self-pay model).
The conventional choice: skip the comprehensive panel, stick with the annual physical, save $500–$700.
The metabolic choice: run the comprehensive panel, find the problems early, intervene before disease develops.
Cost of early intervention: $700 (testing) + $2,000–$5,000/year (clinical monitoring and pharmaceutical treatment if needed).
Cost of late intervention: $0 (not spending money now) + $50,000–$200,000+ in medical costs when you develop Type 2 diabetes, have a cardiovascular event, or experience metabolic decompensation.
Which executive making $200K+ per year is choosing the option that saves $700 today and costs $150,000 tomorrow?
None of them. Not when they understand the math.
The real cost of your annual physical isn't that it's cheap. It's that it's incomplete. It gives you false reassurance.
Beyond the 7: What Else Should You Test?
The 7 markers above are the highest-priority, most-actionable biomarkers for executives. But a truly comprehensive panel should include:
- Lipid particle subfractionation: LDL particle count, small LDL particle percentage, HDL particle count
- Liver function: AST, ALT, albumin, bilirubin (fasting-induced fatty liver is common in insulin-resistant men)
- Kidney function: Creatinine, cystatin C, estimated GFR, urine microalbumin
- Immune function: White blood cell differential, absolute neutrophil count, lymphocyte count
- Nutrient status: Vitamin D, B12, folate, iron (ferritin, TIBC)
- Advanced metabolic markers: Fasting glucose, fasting insulin, 2-hour postprandial glucose (if indicated)
- Micronutrient status: Magnesium, zinc, copper (if clinical indication)
But if you only add the 7 above to your annual physical, you've transformed your health assessment from basic disease screening to meaningful metabolic optimization.
Where to Get Comprehensive Testing in Houston
Comprehensive blood panels are available through several models:
Direct-to-consumer platforms (Function Health, Superpower, WellnessFX): You order, you get tested, you get a dashboard. Cost: $400–$800. Benefit: comprehensive, convenient. Gap: no clinical interpretation or treatment protocol.
Concierge metabolic clinics (like 1836 Wellness): You get tested as part of a clinical assessment. A clinician interprets your results in the context of your health history, designs a treatment protocol if indicated, and provides ongoing monitoring. Cost: $300–$600 (testing) + $200–$500/month (ongoing clinical management) if treatment is needed. Benefit: comprehensive testing + clinical protocol design + outcome accountability.
Traditional functional medicine practitioners: Variable quality, variable cost ($1,000–$3,000 per initial assessment). Some are excellent; others oversell supplementation and underperform on clinical depth.
The choice depends on what you want. If you want data, the D2C platforms are efficient. If you want outcomes, you need clinical involvement.
Why Executives Are Switching to Comprehensive Testing
The executives who have shifted from annual physicals to comprehensive panels did so for one reason: their annual physical was wrong.
They felt bad. Fatigued. Brain fog. Slow metabolism. Declining performance. But their doctor said, "You're fine."
They ran comprehensive testing. Found HOMA-IR of 3.2, hs-CRP of 4.5, free testosterone of 13, HbA1c of 5.9.
Their doctor hadn't been lying. Those markers weren't on the annual physical. The annual physical literally couldn't see them.
Once identified, these markers were addressable. Protocol-driven treatment got their HOMA-IR down to 2.0. Their hs-CRP down to 1.5. Their free testosterone back to 18. Their HbA1c back to 5.6%.
They felt dramatically better. They had more energy. They lost weight. They recovered mental clarity.
The annual physical would have never found any of this. And they would have remained symptomatic, thinking they were "fine" because that's what their lab work said.
The Shift From Disease Screening to Metabolic Optimization
Here's the paradigm shift:
Annual physical model: "Do you have a disease? If not, you're fine."
Comprehensive testing model: "What is your metabolic trajectory? Are you moving toward disease, toward health, or remaining neutral?"
These are different questions. The annual physical asks yes/no. Comprehensive testing asks trajectory.
For an executive, trajectory is everything. An executive with HbA1c 5.8% doesn't have diabetes, but his trajectory is toward diabetes. An executive with HOMA-IR 3.0 doesn't have metabolic syndrome diagnosis, but his trajectory is metabolic dysfunction. An executive with free testosterone 14 doesn't have a medical diagnosis of hypogonadism, but his trajectory is declining.
Identifying trajectory early—before it becomes a diagnosis—is the whole point of health optimization.
Your annual physical can't see trajectory. It sees snapshots.
Comprehensive testing reveals trajectory. And trajectory is actionable.
Next Steps: Getting Tested
If you're a Houston executive ready to move beyond "you're fine" and into actual metabolic assessment, here's your path:
Option 1: Self-directed comprehensive testing
Order through Function Health, Superpower, or WellnessFX. Cost: $500–$800. Timeline: 2 weeks to results.
Benefit: You get comprehensive data and can DIY the interpretation using educational resources and your own research.
Limitation: You won't have clinical guidance on protocol design or treatment, so the "what do I do with this?" question remains.
Option 2: Comprehensive testing + clinical protocol design
Run the 1836 Wellness Executive Panel (45+ markers including all 7 above) with clinical assessment. Cost: $599, with mobile phlebotomy. Includes a Protocol Engine Analysis consultation to design your treatment roadmap if biomarkers indicate need.
Benefit: Comprehensive testing + clinical interpretation + personalized protocol design if indicated. The $599 credits 100% toward any treatment package if you move forward.
Timeline: Initial appointment + labs, then protocol design consultation 5-7 days later.
Summary: Know What Your Annual Physical Can't Tell You
Your annual physical gives you 12 markers and false reassurance.
Comprehensive testing gives you 45–60 markers and actual insight into your metabolic health.
The 7 markers above—HOMA-IR, hs-CRP, ApoB, free testosterone, complete thyroid panel, HbA1c, and homocysteine—are the ones your doctor skipped.
They're also the ones that matter most for your longevity, performance, and preventive optimization.
Know them. Test them. If they're suboptimal, address them now—before they become diagnoses.
Your annual physical says you're fine. Comprehensive testing tells you whether that's true.
Next Steps
Ready to move beyond the annual physical?
1836 Wellness Precision Diagnostic: 80 biomarkers including all 7 critical markers above. Mobile phlebotomy. $599, with credits toward treatment.
Apply now — book the $599 Precision Diagnostic
Get the data your annual physical missed. Understand your actual metabolic trajectory. Design the protocol to optimize it.